Conference Coverage

VIDEO: 'Target: Stroke' program hopes to add hospitals, increase timely treatment


 

SAN DIEGO – The average proportion of ischemic patients who got tissue plasminogen activator within an hour of arriving at participating hospitals increased from 30% before initiation of the Target: Stroke project to 53% afterward. We interviewed Dr. Gregg C. Fonarow about the new phase II of Target: Stroke, launched at the International Stroke Conference , which aims for timely door-to-needle treatment in 75% of stroke patients.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel .

Recommended Reading

Video: Positive trends for outcomes in uric acid stroke trial gives optimism
MDedge Neurology
VIDEO: Postpartum elevated thrombosis risk lasts 12 weeks
MDedge Neurology
Postpartum thrombosis risk high for 12 weeks
MDedge Neurology
Magnesium Treatment May Not Improve Stroke Outcome
MDedge Neurology
Treating With Uric Acid and t-PA May Reduce Stroke Disability
MDedge Neurology
VIDEO: Longer period of postpartum thromboembolic risk raises therapeutic questions
MDedge Neurology
VIDEO: Moderate exercise reduced women’s stroke risk
MDedge Neurology
Moderate exercise reduces female stroke risk
MDedge Neurology
VIDEO: Highlights of the Annual Stroke Conference
MDedge Neurology
'Target: Stroke' program gets most patients timely treatment
MDedge Neurology

Related Articles